𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression

✍ Scribed by Paul E. Holtzheimer III; Thomas W. Meeks; Mary E. Kelley; Mustafa Mufti; Raymond Young; Kimberly McWhorter; Nancie Vito; Ronald Chismar; Sinéad Quinn; Sherry Dey; Eve H. Byrd; William M. McDonald

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
105 KB
Volume
23
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

Depression in older adults is often associated with cognitive abnormalities and may predict later development of a primary cognitive disorder. This double‐blind, randomized, placebo‐controlled pilot study was designed to assess the safety and efficacy of galantamine augmentation of antidepressant treatment for depressive and cognitive symptoms in older adults with major depression.

Methods

Thirty‐eight, non‐demented older adults (age >50) with major depression were randomized to receive galantamine or placebo augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram). Mood and cognitive status were monitored for 24 weeks using the 24‐item Hamilton Rating Scale for Depression and the Repeatable Battery for the Assessment of Neuropsychological Status.

Results

Both groups showed significant improvements in mood and cognition over 24 weeks, but no significant difference was found in change over time between groups. An exploratory post‐hoc analysis suggested that patients randomized to galantamine had lower depression scores compared to patients in the placebo group after 2 weeks of treatment. Dropout was high with more subjects randomized to antidepressant plus galantamine withdrawing early from the study.

Conclusions

This pilot study failed to demonstrate a benefit for galantamine augmentation of antidepressant medication in the treatment of depression in older adults. Future studies should explore strategies for reducing dropout in such longitudinal trials and more carefully assess time to response with cholinesterase inhibitor augmentation. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Randomized double-blind placebo-controll
Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study
✍ Gregory H. Pelton; Oliver L. Harper; Matthias H. Tabert; Harold A. Sackeim; Niko 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Abstract ## Objective To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment. ## Methods Twenty‐three elderly (>50 years old) depressed, cognitively impaired (DEP‐CI) patients participated in a pilot study. W

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode

A randomised, double-blind, placebo-cont
A randomised, double-blind, placebo-controlled, 5-weeks' study of org 3770 (mirtazapine) in major depression
✍ M. C. Khan 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

Fifty-four hospitalised and outpatients with a DSM 111 diagnosis of major depressive disorder and 21-item HPRSD score of 2 18, were randomised to 5 weeks' of treatment with either Org 3770 (n=27; 20-60mg/day) or placebo (n = 27). The treatment with Org 3770 resulted in statistically significant and

Pindolol augmentation of selective serot
Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression
✍ Rebecca Segrave; Pradeep J. Nathan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 365 KB 👁 1 views

Co-administration of pindolol with SSRIs in patients with depression has been suggested as a way to both hasten and augment antidepressant response. Clinical trials have examined the efficacy of this treatment regime and conflicting results have been reported. The present review briefly presents the